INDICATIONS FOR USE

Testosterone cypionate is indicated for testosterone replacement therapy (TRT) in men with primary or secondary hypogonadism. It is used to restore normal testosterone levels in cases of deficiency due to conditions such as testicular failure, pituitary dysfunction, or aging-related testosterone decline. Off-label uses include muscle preservation and performance enhancement in certain clinical scenarios.

ROUTE OF ADMINISTRATION

• Intramuscular injection

• Subcutaneous injection

COMMON INITIAL DOSING REGIMENS

• The typical starting dose is 50–100 mg intramuscularly every 7–14 days. Doses may be adjusted to 75–200 mg every 3-7 days based on serum testosterone levels and clinical response.

• NOTE: We believe that taking smaller doses of testosterone more frequently better replaces normal physiology and results in dramatically improved outcomes. This approach is referred to as “micro-dosing”. A typical starting dose might be 10 mg daily, 7 days per week.

MECHANISM OF ACTION

• Testosterone cypionate is a synthetic esterified form of testosterone that is slowly released into the bloodstream after intramuscular administration. It binds to androgen receptors in target tissues, activating gene transcription and protein synthesis. This action facilitates secondary male sexual characteristics, muscle growth, bone density maintenance, and erythropoiesis.

• The long half-life of testosterone cypionate (~8 days) ensures a sustained increase in serum testosterone, making it suitable for periodic administration.

COMMON SIDE EFFECTS

• Endocrine: Gynecomastia, testicular atrophy, and suppression of endogenous testosterone production.

• Cardiovascular: Hypertension, polycythemia (elevated hematocrit), and potential increased risk of cardiovascular events.

• Dermatologic: Acne, oily skin, and hair loss due to androgenic activity.

• Metabolic: Weight gain, alterations in lipid profiles (e.g., decreased HDL), and fluid retention.

• Psychological: Mood swings, aggression, or increased libido.

• Rare: Deep vein thrombosis or pulmonary embolism in predisposed individuals.

CONTRAINDICATIONS

• Absolute: Known or suspected prostate cancer, breast cancer in men, and hypersensitivity to testosterone cypionate or its components.

• Relative: Severe heart failure, sleep apnea, erythrocytosis (hematocrit >54%), and uncontrolled hypertension. Caution is also advised in patients with a history of thromboembolic events or liver dysfunction.

LEARN MORE

• Evidence hound? Review our comprehensive listing of PubMed direct links to original research related to this medication.